Add to favourites

No account yet? Register

For Healthcare Professionals
Melatonin Therapy Optimisation Programme

Sleep is essential at all stages of life, but in childhood, where neuronal development occurs, adequate sleep is particularly essential.1 A growing body of evidence indicates that abnormal melatonin secretion may be the cause of insomnia in children with neurodevelopmental disorders such as ASD.2,3

Despite the availability of a suitably licensed alternative, and guidance on the judicious use of specials, melatonin that is either unlicensed or off-label continues to account for high levels of prescribing.4,5

The Melatonin Therapy Optimisation Programme is designed to support a systematic, consistent and efficient approach to identify appropriate patients who may benefit from a clinical review (including their medication). Details of how to access the scheme are available by contacting Flynn Pharma.

1. Dahl, E., Sleep (2007) 30 (90); 1079-80).

2. Leu, R.M. et al Jnl Autism Dev Discord (2011) 41 (4) 427-33

3. Melke, J., et al. Mol Psychiatry (2008); 13 (1); 90-8

4. GOV.UK. (2014). Off-label or unlicensed use of medicines: prescribers’ responsibilities.

5. NHSBSA. (2022). Volume and cost of special order products.

How to apply

The Melatonin Therapy Optimisation Programme is delivered as a service to Medicine, and is fully funded by Flynn Pharma Ltd. To find out more about the Melatonin Therapy Optimisation Programme, please contact Flynn Pharma.

PRODUCT: Slenyto®

Become an NDD Community Member

Join our community as a Member and keep up to date on the latest developments.

Related Service Support Items